Dr Reddy's Laboratories fell 1.25% to Rs 2,190 at 15:15 IST on BSE after net profit rose 7.43% to Rs 360.93 crore on 12.49% increase in total income to Rs 2882.48 crore in Q1 June 2013 over Q1 June 2012.
The company announced the result during trading hours today, 30 July 2013.
Meanwhile, the S&P BSE Sensex was down 251 points, or 1.28%, to 19,342.28.
On BSE, 1.08 lakh shares were traded in the counter as against an average daily volume of 27,305 shares in the past one quarter.
The stock turned volatile after the result was announced. The stock rose 1.99% at the day's high of Rs 2,261.70. It fell 3.01% at the day's low of Rs 2,151.
The stock had hit a 52-week high of Rs 2,400.75 on 15 July 2013. The stock had hit a 52-week low of Rs 1,603 on 31 July 2012.
More From This Section
The stock had underperformed the market over the past one month till 29 July 2013, rising 0.10% compared with the Sensex's 1.02% rise. The scrip had, however, outperformed the market in past one quarter, rising 11.29% as against Sensex's 1.06% rise.
The large-cap company has an equity capital of Rs 85.03 crore. Face value per share is Rs 5.
Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 13% to Rs 568.90 crore in Q1 June 2013 over Q1 June 2010.
Research and development (R&D) expense rose 55% to Rs 243 crore in Q1 June 2013 over Q1 June 2010. The company said that the jump in R&D expense is in line with the increased focus on complex formulations, differentiated portfolios and biosimilars.
The company's selling, general & admistrative (SG&A) expenses rose by 6% to Rs 879.40 crore in Q1 June 2013 over Q1 June 2010.
The company launched 18 new products, filed 12 new product registrations and filed 5 Drug Master Files (DMFs) globally in Q1 June 2013.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars, differentiated formulations and new chemical entities (NCEs).
Powered by Capital Market - Live News